- Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid LeukemiaZha, Jie; Wang, Ying; Li, Zhenling; Lin, Zhijuan; Cai, Yun; Gong, Tiejun; Md, Wei Yang; Xie, Siting; Huang, Zhenqi; Shi, Pengcheng; Fu, Lin; Wang, Jinghua; Fu, Xiangjun; Feng, Xianqi; Su, Liping; Luo, Jianmin; Yang, Lin; Chen, Biyun; Xie, Ying; Zhu, Yu; Du, Xin; Jiang, Yirong; Li, Zhifeng; Xu, Bing65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.被引 1
- Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 TrialHuang, Rui; Lin, Xiaonan; Zhang, Yuming; Su, YongZhong; Wang, Caixia; Zhou, Jihao; Huang, Zhenqian; Huang, Jinxiong; Zhang, Xiong; Zhao, Ying; Liang, Yuexiong; Wang, Xiaotao; Gu, Xuekui; He, Honghua; Zheng, Yaling; Tu, Sanfang; Chen, FeiHeng; Lin, Shaoze; Wang, Yaya; Dong, Ying; Huang, Pengcheng; Liu, Zenghui; Xu, Xiaoli; Liang, Zhao; Zhou, Xuan; Li, Meifang; Luo, Man; Wu, Ming; Jiang, Fang; Liu, Qin; Zeng, Hui; Song, Chaoyang; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid LeukemiaWeng, Guangyang; Zhang, Yu; Yu, Guopan; Xu, Na; Sun, Zhiqiang; Lin, Dongjun; Liang, Xinquan; Deng, Lan; Xiao, Jie; Zhang, Hongyu; Guo, Ziwen; Jin, Hua; Du, Xin; Liu, Qifa64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 2
会议论文
Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
2被引9阅读
